Preliminary Report - ID Mapping

Traditionally the BioGRID repository has required that all curated data map to a peer-reviewed Pubmed ID before public release. With the rapidly evolving global health crisis of COVID-19, we've decided to temporarily suspend that requirement in order to more rapidly curate publications released on platforms such as BiorXiv and provide that data to the research community. As a result, some of our download files currently require a Pubmed ID to output correctly (such as PSI-MI TAB, BioGRID TAB2, and PSI-MI XML). We recommend anyone wanting to get the most accurate download available to please use our newest TAB3 format instead.

In order to maintain compatibility, we've temporarily assigned new custom IDs in place of Pubmed IDs for each of these publications. So, if you see one of these IDs, you can use the following listing to determine the associated DOI for each.

WARNING - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

Custom ID DOI AUTHOR DATASET
888800000002 10.1101/2020.03.29.20041962 Gao T (2020) Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
888800000003 10.1101/2020.02.16.951723 Sun C (2020) SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
888800000004 10.1101/2020.03.16.994236 Procko E (2020) The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2
888800000005 10.1101/2020.03.14.988345 Wang K (2020) SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
888800000006 10.1101/2020.02.17.951848 Zhou Q (2020) Structure of dimeric full-length human ACE2 in complex with B0AT1
888800000007 10.1101/2020.02.26.964882 Jin Z (2020) Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]
888800000008 10.1101/2020.03.29.013490 Wang C (2020) Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
888800000009 10.1101/2020.03.25.996348 Dai W (2020) Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease
888800000010 10.1101/2020.03.15.992883 Joyce MG (2020) A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
888800000011 10.1101/2020.03.16.993386 Gao Y (2020) Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target
888800000012 10.1101/2020.03.31.019216 Liang Q (2020) Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis
888800000013 10.1101/2020.04.15.042085 Bestle D (2020) TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
888800000016 10.1101/2020.04.14.042010 Chi X (2020) Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
888800000017 10.1101/2020.04.06.20055475 Ye L (2020) Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
888800000018 10.1101/2020.04.19.049643 Zeng X (2020) Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy
888800000019 10.1101/2020.04.23.057265 Peng Q (2020) Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus
888800000020 10.1101/2020.04.22.046565 Liu Y (2020) Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2
888800000021 10.1101/2020.04.21.053017 Walker A (2020) Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
888800000022 10.1101/2020.04.17.047498 Rosas Lemus M (2020) The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine
888800000023 10.1101/2020.04.19.048710 Zhao X (2020) Broad and differential animal ACE2 receptor usage by SARS-CoV-2
888800000024 10.1101/2020.04.26.061705 Viswanathan T (2020) Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus
888800000025 10.1101/2020.04.29.068890 Rut W (2020) Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design
888800000026 10.1101/2020.04.27.063180 Hillen HS (2020) Structure of replicating SARS-CoV-2 polymerase
888800000027 10.1101/2020.04.29.068098 Sun Z (2020) Mass spectrometry analysis of newly emerging coronavirus HCoV-19 spike S protein and human ACE2 reveals camouflaging glycans and unique post-translational modifications
888800000028 10.1101/2020.05.03.073080 Vuong W (2020) Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
888800000029 10.1101/2020.05.02.20086876 Zhang D (2020) Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)
888800000030 10.1101/2020.05.05.079202 Huo J (2020) Neutralization of SARS-CoV-2 by destruction of the prefusion Spike
888800000031 10.1101/2020.05.06.079830 Zha L (2020) Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles
888800000032 10.1101/2020.05.02.043554 Gunther S (2020) Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease
888800000033 10.1101/2020.05.01.20077743 Wu Y (2020) A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
888800000034 10.1101/2020.05.03.074914 Liu X (2020) Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
888800000035 10.1101/2020.05.21.109157 Lui I (2020) Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
888800000036 10.1101/2020.05.21.107870 Partridge LJ (2020) Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line
888800000037 10.1101/2020.05.13.092478 Chiodo F (2020) Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota
888800000038 10.1101/2020.05.12.091298 Seydoux E (2020) Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
888800000039 10.1101/2020.05.21.107565 Zang J (2020) Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
888800000040 10.1101/2020.05.12.092171 Zhou X (2020) Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation
888800000041 10.1101/2020.06.17.156455 Stukalov A (2020) Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV
888800000042 10.1101/2020.06.05.135921 Bertoglio F (2020) SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
888800000043 10.1101/2020.06.05.135699 Moustaqil M (2020) SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.
888800000044 10.1101/2020.06.17.157982 Starr TN (2020) Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
888800000045 10.1101/2020.06.05.134114 Daly JL (2020) Neuropilin-1 is a host factor for SARS-CoV-2 infection
888800000046 10.1101/2020.06.17.158121 Cubuk J (2020) The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
888800000047 10.1101/2020.06.09.142794 Yang Y (2020) The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.
888800000048 10.1101/2020.06.02.130161 Hanke L (2020) An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
888800000049 10.1101/2020.06.17.156471 Conceicao C (2020) The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins
888800000050 10.1101/2020.06.07.138677 Luan X (2020) Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376
888800000051 10.1101/2020.06.02.129098 Lv Z (2020) Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
888800000052 10.1101/2020.06.06.137513 Lou Y (2020) Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries
888800000053 10.1101/2020.05.27.118117 Douangamath A (2020) Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
888800000054 10.1101/2020.06.16.155812 Li J (2020) Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin
888800000055 10.1101/2020.06.15.153387 Beddingfield B (2020) The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
 
covid/unpublished.txt · Last modified: 2020/08/05 13:15 by biogridadmin